SCHEMBL23970627

SCHEMBL23970627

CC(C)(C)OC(=O)c1ccc(Cl)nc1CCCCCO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35
GABRA6 Q16445 1/20 0.35
GABRG1 Q8N1C3 1/20 0.35
GABRG3 Q99928 1/20 0.35
GABRQ Q9UN88 1/20 0.35
CYP4F2 P78329 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30850136 1.00 TDP1 (0.38) TDP1LMNAKMT2AGABRPGABRD
SCHEMBL30159250 0.88 TDP1 (0.39) TDP1GABRPGABRDGABRA1GABRB1
SCHEMBL23970518 0.88 TDP1 (0.39) TDP1GABRPGABRDGABRA1GABRB1
SCHEMBL23971334 0.82 TDP1 (0.37) TDP1LMNAKMT2AGABRPGABRD
SCHEMBL23971072 0.81 GABRP (0.43) LMNAKMT2AGABRPGABRDGABRA1
SCHEMBL23971359 0.80 ACACB (0.40) LMNAKMT2AATRMAPKAPK2
SCHEMBL30159082 0.79 GABRP (0.50) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL28950501 0.79 PSMD10 (0.38) LMNAKMT2A
SCHEMBL30158994 0.79 PSMD10 (0.38) LMNAKMT2A
SCHEMBL24850654 0.77 KMT2A (0.32) LMNAKMT2AATRMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 TDP1 199/4885LMNA 2684/4885KMT2A 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.